GAITHERSBURG, Md, July 14 (Reuters) - U.S. advisers neared a vote on whether a GlaxoSmithKline Plc (GSK.L) diabetes drug carries too much heart risk to stay on the market, hearing final conflicting pleas Wednesday from a patient and a public health advocate.
